MinK Therapeutics

MinK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of invariant Natural Killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a unique subset of T cells that combine the persistent memory response with the rapid cytolytic properties of Natural Killer (NK) cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapies, as these cells naturally home to tissues, contribute to the clearance of tumor and infected cells, and suppress Graft-versus-Host Disease (GvHD).